Industry kudos to BioMarin
November 6, 2020This week, BioMarin Pharmaceutical reported third-quarter sales revenues of $477 million, beating analyst predictions and adjusting its earnings guidance. This industry-leading maker of drugs to treat rare diseases shared the details of its most recent success and financial highlights in a press release available at https://investors.biomarin.com/press-releases.
“The AlphaGroup of Medical Communications companies is pleased to see growth for BioMarin, who, amidst the COVID-19 pandemic, continued in their mission to help patients with vital medicines,” said AlphaGroup founder and partner Ed Shifflett, PhD. “We congratulate them on this milestone and we are excited to follow their pioneering discoveries in future data releases.”
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a significant benefit over existing products. Their portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.
The AlphaGroup is a team of scientific and medical affairs communication specialists supporting AlphaBioCom, AlphaScientia, and AlphaQsci agencies. The company is made up of PhD scientists, MDs, PharmDs, nurses, designers, and communication and innovation experts. Their collective genius delivers the highest-quality scientific, medical affairs, and outcomes communication services anywhere in the world.